MARKET

NVS

NVS

Novartis
NYSE

Real-time Quotes | Nasdaq Last Sale

88.65
+0.97
+1.11%
After Hours: 88.85 +0.2 +0.22% 19:49 05/19 EDT
OPEN
88.05
PREV CLOSE
87.68
HIGH
89.08
LOW
88.01
VOLUME
3.82M
TURNOVER
0
52 WEEK HIGH
95.17
52 WEEK LOW
79.09
MARKET CAP
196.15B
P/E (TTM)
8.26
1D
5D
1M
3M
1Y
5Y
Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition
Alnylam's (ALNY) portfolio of approved drugs is witnessing strong uptake so far while its pipeline is progressing well. However, stiff competition in the target market remains a woe.
Zacks · 12h ago
Seattle's Max Foundation launches global push to serve cancer patients
The foundation is working with drugmaker Novartis to provide eligible patients in 28 low- and middle-income countries with breast cancer treatments.
American City Business Journals · 2d ago
Analyzing Novartis's Short Interest
Novartis's (NYSE:NVS) short percent of float has risen 3.57% since its last report. The company recently reported that it has 6.56 million shares sold short, which is 0.29% of all regular shares that are available for trading.
Benzinga · 2d ago
5 Value Stocks In The Healthcare Sector
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be...
Benzinga · 3d ago
Global Blood, Impel Pharma could be M&A targets after Biohaven deal - analysts
Global Blood Therapeutics (NASDAQ:GBT) may be a potential acquisition candidate in the biotech space following Pfizer (PFE)'s deal to acquire Biohaven Pharmaceutical for about $11.6 billion, according to a Wedbush
Seekingalpha · 4d ago
BRIEF-Sandoz Launches First Generic Pirfenidone In U.S. For Patients With Idiopathic Pulmonary Fibrosis
reuters.com · 05/12 20:55
Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis
Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped.
Investor's Business Daily · 05/12 16:21
Novartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer
Latest in HR+/HER2- metastatic breast cancer, including data on CDK recycling with Kisqali® plus endocrine therapy, further MONALEESA-2 quality of life and overall survival analyses, and a new biomarker analysis of Piqray® plus fulvestrantData for Tafinlar...
GlobeNewswire · 05/12 14:28
More
No Data
Learn about the latest financial forecast of NVS. Analyze the recent business situations of Novartis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
33.33%Buy
33.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average NVS stock price target is 104.40 with a high estimate of 108.00 and a low estimate of 100.00.
High108.00
Average104.40
Low100.00
Current 88.65
EPS
Actual
Estimate
0.430.861.281.71
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 1.56K
Institutional Holdings: 244.59M
% Owned: 11.05%
Shares Outstanding: 2.21B
TypeInstitutionsShares
Increased
327
10.73M
New
140
1.56M
Decreased
464
20.00M
Sold Out
73
808.72K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.15%
Pharmaceuticals & Medical Research
+0.51%
Key Executives
Non-Executive Chairman/Independent Director
Joerg Reinhardt
Chief Executive Officer/Executive Board
Vasant Narasimhan
Non-Executive Vice Chairman/Lead Director/Independent Director
Enrico Vanni
Chief Financial Officer/Executive Board
Harry Kirsch
Chief Human Resource Officer
Robert Kowalski
Chief Compliance Officer/Chief Risk Officer/Executive Board
Klaus Moosmayer
Executive Board
James Bradner
Executive Board
Victor Bulto
Executive Board
Karen Hale
Executive Board
Steffen Lang
Executive Board
Richard Saynor
Executive Board
John Tsai
Executive Board
Marie-France Tschudin
Secretary
Charlotte Pamer- Wieser
Non-Executive Independent Director
Nancy Andrews
Non-Executive Independent Director
Ton Buechner
Non-Executive Independent Director
Patrice Bula
Non-Executive Independent Director
Elizabeth Doherty
Non-Executive Independent Director
Ann Fudge
Non-Executive Independent Director
Bridgette Heller
Non-Executive Independent Director
Simon Moroney
Non-Executive Independent Director
Charles Sawyers
Non-Executive Independent Director
Frans van Houten
Non-Executive Independent Director
Andreas von Planta
Non-Executive Independent Director
William Winters
No Data
No Data
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Webull offers kinds of Novartis AG (ADR) stock information, including NYSE:NVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVS stock methods without spending real money on the virtual paper trading platform.